Search
Clenoliximab
go.drugbank.com/drugs/DB06241ExperimentalClenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.
TTP889
go.drugbank.com/drugs/DB05131InvestigationalTTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system.
Baicalein
go.drugbank.com/drugs/DB16101InvestigationalBaicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of Baicalein Tablets
Categories: Compounds used in a research, industrial, or household settingSF1126
go.drugbank.com/drugs/DB05210InvestigationalSF1126 is an integrin-targeted PI3 kinase inhibitor.
Imolamine
go.drugbank.com/drugs/DB09284InvestigationalImolamine is a compound with a molecular weight of 260.33 g/mol with the formula diethyl[2-{5-imino-3-phenyl-4,5-dihydro-1,2,3-oxadiazol,-4-yl)ethyl]amine. … It is developed under the brand name Coremax by Novartis consumer health SA.
CK0802
go.drugbank.com/drugs/DB15866InvestigationalCK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching.
Allovectin-7
go.drugbank.com/drugs/DB17439InvestigationalAllovectin-7 or allovectin-7(r) is a lipid complex that contains the DNA sequences encoding HLA-B7 and beta-2 microglobulin.
Cediranib
go.drugbank.com/drugs/DB04849InvestigationalThe novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. … It is being developed clinically as a once-daily oral therapy for the treatment of cancer.